MedTrace Logo

Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)

NCT04562805 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2400

Last updated 2024-10-16

No results posted yet for this study

Summary

The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor : Resolute Onyx).

Conditions

Interventions

DEVICE

DynamX Bioadaptor

DynamX Bioadaptor Treatment

DEVICE

Resolute Onyx

Resolute Onyx Treatment

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Elixir Medical Corporation

    lead INDUSTRY

Principal Investigators

  • David Erlinge, MD, PhD · Skane University Hospital, Lund

  • Stefan James, MD, PhD · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2024-09-05
Completion
2028-07-31
FDA Device
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562805 on ClinicalTrials.gov